Oral enzyme therapy and experimental rat mammary tumor metastasis.
Oral enzyme therapy and experimental rat mammary tumor metastasis.
复制标题
口服酶疗法和实验性大鼠乳腺肿瘤转移。
DOI：
10.1016/s0024-3205(99)00529-9
复制
发表时间：
1999
期刊：
影响因子：
6.1
通讯作者：
Wynder,EL
中科院分区：
文献类型：
--
作者：
Cohen,LA;Aliaga,C;Pittman,B;Wynder,EL
尽管多年来人们对口服蛋白水解酶的医学应用很感兴趣，但它们对晚期癌症的疗效仍存在相当大的争议。鉴于此，本研究的目的是评估不同剂量的口服猪胰腺制剂对R13762可移植大鼠乳腺肿瘤生长和转移的抑制作用。5组12只F-344雌性退役种猪用2mm3肿瘤植入物原位接种，饲喂以下饲粮：(1)AIN-76A饲粮+ 20%猪胰腺制剂（PPP）；(2) AIN-76A + 20% PPP + 10 mg枸橼酸mg /大鼠/天；(3) ain-76a + 2% ppp；(4) AIN-76A + 2% PPP + 10 mg柠檬酸mg和(5)仅AIN-76A（对照）。监测原发肿瘤的发展40天，并在牺牲后切除肺，染色并定量转移灶。根据转移灶半径将其分为小（<1mm）、中（1-3mm）、大（bbb3mm） 3组，计算体积。在研究期间，口服酶制剂对原发肿瘤生长或体重变化没有影响。五组大鼠肺转移率（发生率）无显著差异。然而，在肺病灶的三种大小类别中，只有在2% PPP组补充Mg++的大（bbb3mm）体积亚组发生率降低。当评估肺病灶的平均数量/大鼠时，20% PPP组的频率最高，对照组的频率最低，重要的例外是2% PPP + Mg++组（大体积），其频率在所有治疗组中最低。总的来说，与不补充Mg++的PPP组相比，Mg++的存在导致每只大鼠肺病灶的平均数量显著减少。类似的结果，当病灶量化的转移体积，而不是频率。这项实验动物研究的结果表明，为了显示PPP对R13762肿瘤转移性传播的有效抑制，需要更低剂量的PPP和更多数量的动物，以解释模型的高度可变性。
Although there has been much interest over the years in the medical use of orally administered proteolytic enzymes, there is considerable controversy about their efficacy against advanced stages of cancer. In light of this, the goal of the present study was to assess the inhibitory effects of different doses of an orally administered porcine pancreas preparation on the growth and metastasis of the R13762 transplantable rat mammary tumor. Five groups of 12 F-344 female retired breeders were inoculated orthotopically with a 2mm3tumor implant and placed on the following diets: (1) AIN-76A diet + 20% porcine pancreas preparation (PPP); (2) AIN-76A + 20% PPP + 10 mg Mg citrate/rat/day; (3) AIN-76A + 2% PPP; (4) AIN-76A + 2% PPP + 10 mg Mg citrate and (5) AIN-76A only (control). Primary tumor development was monitored for 40 days and following sacrifice, lungs were excised, stained and metastatic foci quantitated. Metastatic foci were sorted into 3 groups based on their radii: small (<1mm), medium (1–3mm) and large (>3mm), and volumes calculated. The oral enzyme preparation had no effect on primary tumor growth or on body weight change over the duration of the study. The percent (incidence) of rats with pulmonary metastases among the five groups were not significantly different. However, among the three size categories of pulmonary foci, decreased incidence was found only in the large (>3mm) volume subset of the 2% PPP group supplemented with Mg++. When assessed in terms of mean number of pulmonary foci/rat, the 20% PPP group exhibited the highest and controls the lowest frequency with the important exception of the 2% PPP + Mg++group (large volume) which exhibited the lowest frequency of all treatment groups. In general, the presence of Mg++resulted in marked decreases in mean number of pulmonary foci/rat compared to groups fed PPP without the Mg++supplement. Similar results were obtained when foci were quantitated in terms of metastic volume rather than frequency. The results of this laboratory animal study suggest that to show effective inhibition of metastatic dissemination of the R13762 tumor by PPP, lower doses of PPP and larger numbers of animals, to account for the high variability in the model, will be required.